Adamas appoints new Chief Medical Officer, Adrian Quartel, MD
October 01 2020 - 9:15AM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to
developing and delivering medicines that make a meaningful
difference to people affected by neurological diseases, today
announced the appointment of Adrian Quartel, MD as Chief Medical
Officer. As a member of the executive leadership team, Adrian will
provide leadership and direction for all scientific and medical
functions.
“We are delighted to welcome Adrian to our
leadership team to further accelerate the progress and execution of
our long-term growth strategy,” said Neil McFarlane, Chief
Executive Officer. “His proven track record in drug development and
extensive clinical experience will be especially valuable at this
pivotal time as we build our development efforts to expand our
reach to more patients.”
“I am excited to join a company which reflects
my passion to make an impact on patients with unmet medical needs,”
said Adrian Quartel, MD. “I look forward to partnering with the
Adamas team and applying my broad industry experience to help us
maximize the opportunity to address serious neurological
diseases.”
Adrian brings over 20 years of global drug
development and pharmaceutical experience, both in academia and
industry. He was most recently global head of Medical Affairs at
BioMarin, where he oversaw the launch of six products. Prior to
BioMarin, Adrian held senior positions leading clinical development
and as principal investigator for several studies at Chiltern. He
also served in pharmacovigilance, clinical development, and medical
affairs roles at Paraxel, Icon and, Astellas. Prior to joining the
industry, Adrian worked as a clinical research fellow at UCLA Cedar
Sinai and as a resident in cardio-thoracic surgery at Erasmus
University Medical Center.
Adrian received his medical degree from Erasmus
University Medical School, Rotterdam, in the Netherlands, and his
post graduate specialization in pharmaceutical medicine from the
Faculty of Pharmaceutical Medicine in London. He is board certified
by the General Medical Council (GMC) in pharmaceutical medicine in
the United Kingdom.
About AdamasAt Adamas our
vision is clear – to deliver innovative medicines that reduce the
burden of neurological diseases on patients, caregivers, and
society. We are a fully integrated company focused on growing a
portfolio of therapies to address a range of neurological diseases.
For more information, please visit www.adamaspharma.com.
Contacts:
Media:Sarah MathiesonVice President, Corporate
Communications510-450-3528smathieson@adamaspharma.com |
Investors:Peter VozzoManaging Director,
Westwicke443-213-0505peter.vozzo@westwicke.com |
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024